21.9 C
New York
Thursday, July 3, 2025

Tag: infants

Innovative Molecules Offer Good News in the Fight Against HIV and Other Viral Infections

INRS team is exploring the potential of saponins, a group of natural molecules found in many plants LAVAL, QC, July 3, 2025 /CNW/ - Innovative, nontoxic...

OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients

OXLUMO has been shown to significantly reduce urinary oxalate, which drives the progression of PH1 Disease1 MISSISSAUGA, ON, July 2, 2025 /CNW/ - Alnylam Canada ULC...

RECKITT BENCKISER SHAREHOLDER ALERT BY FORMER LOUISIANA ATTORNEY GENERAL: KAHN SWICK & FOTI, LLC REMINDS INVESTORS WITH LOSSES IN EXCESS OF $100,000 of Lead...

NEW YORK and NEW ORLEANS, July 01, 2025 (GLOBE NEWSWIRE) -- Kahn Swick & Foti, LLC (“KSF”) and KSF partner, former Attorney General of Louisiana, Charles C. Foti, Jr., remind investors that they have until August 4, 2025 to file lead plaintiff applications in a securities class action lawsuit against Reckitt Benckiser Group PLC (“Reckitt” or the “Company”) (OTC: RBGLY), if they purchased the Company’s American Depositary Shares (“ADSs”) between January 13, 2021 and July 28, 2024, inclusive (the “Class Period”). This action is pending in the United States District Court for the Southern District of New York.

Novo Holdings portfolio company Kate Farms acquired by Danone

Novo Holdings led Kate Farms' Series C financing in 2022 and supported its continued growth as the company's largest institutional investor Transaction highlights the Planetary...

RBGLY Investors Have Opportunity to Lead Reckitt Benckiser Group PLC Securities Fraud Lawsuit

NEW YORK, June 30, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares ("ADSs") of...

New Data for Nusinersen Underscore Biogen’s Commitment to Advancing Clinical Research to Improve Outcomes in SMA

CAMBRIDGE, Mass., June 27, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced new data that reinforce the clinical impact of nusinersen across a broad spectrum of individuals affected by spinal muscular atrophy (SMA). These latest findings from Part C of the DEVOTE trial evaluating a higher dose regimen of nusinersen and the NURTURE trial which evaluated the approved 12 mg regimen (SPINRAZA®) in clinically presymptomatic SMA were presented at the SMA Research & Clinical Care Meeting hosted by Cure SMA in Anaheim, Calif. Biogen’s applications for the higher dose regimen of nusinersen are currently under review in the U.S., Europe, Japan and other global markets. The higher dose regimen of nusinersen comprises a more rapid loading regimen – two 50 mg doses 14 days apart – and a higher maintenance regimen – 28 mg every four months.

UCB announces positive results from GEMZ Phase 3 study of fenfluramine in CDKL5 deficiency disorder

Phase 3 study met primary and most key secondary clinical endpointsThis marks the third developmental and epileptic encephalopathies (DEE) population for fenfluramine with positive phase...

Camilia Tummy Liquid Doses From Boiron Winner Of “Baby Accessory Product of the Year”

Annual Awards Program Recognizes Innovative Companies, Services and Products Within the Baby Care Industry
Annual Awards Program Recognizes Innovative Companies, Services and Products Within the Baby Care Industry

Bavarian Nordic Announces the Initiation of Clinical Trials of Mpox Vaccine in Infants and Pregnant Women

COPENHAGEN, Denmark, June 26, 2025 – Bavarian Nordic A/S (OMX: BAVA) announced today the initiation of the first of two clinical trials designed to support approval and use of the MVA-BN® mpox/smallpox vaccine in vulnerable populations: infants under 2 years of age and pregnant and breastfeeding women

Gold Coast Health Plan Announces Inaugural Grant Awards to Expand Health Care Access Across Ventura County

Resilience, Innovation, Sustainability & Equity (RISE) Grant Program Launches with nearly $22-Million Investment in Community-Based Care CAMARILLO, Calif., June 25, 2025 /PRNewswire/ -- Gold Coast...

ROSEN, A GLOBAL AND LEADING LAW FIRM, Encourages Reckitt Benckiser Group PLC Investors to Secure Counsel Before Important Deadline in Securities Class Action –...

NEW YORK, June 24, 2025 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of American Depositary Shares (“ADSs”) of Reckitt Benckiser Group PLC (OTC: RBGLY) between January 13, 2021 through July 28, 2024, both dates inclusive (the “Class Period”), of the important August 4, 2025 lead plaintiff deadline.

JPMA is now the Baby Safety Alliance

Organization will continue to champion safer products for babies and peace of mind for parents MT. LAUREL, N.J., June 24, 2025 /PRNewswire/ -- The Juvenile Products Manufacturers...

Safety 1st Launches onBoard™ Slide DLX Infant Car Seat with Innovative SafetySlide™ Base

A first of its kind car seat design that makes it easier than ever to get baby in and out of the car FOXBOROUGH, Mass.,...

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTagsInfants